Evidence map›Paper›PMID 36890803›Full record

ArticleSAGE open medical case reports2023

A case of epidermal growth factor receptor tyrosine kinase inhibitor effectiveness in epidermal growth factor receptor mutation-positive squamous cell carcinoma.

Sosuke Matsumura, Satoshi Ano, Norihiro Kikuchi, Michiko Masuda, Hajime Osawa, Yuzuru Kondo, Yukio Ishii, Nobuyuki Hizawa

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in SAGE open medical case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Sosuke MatsumuraDepartment of Respiratory Medicine, University of Tsukuba, Tsukuba, Japan.
Satoshi AnoDepartment of Respiratory Medicine, University of Tsukuba, Tsukuba, Japan.ORCID https://orcid.org/0000-0001-5349-1868
Norihiro KikuchiDepartment of Respiratory Medicine, National Hospital Organization Kasumigaura Medical Center, Tsuchiura, Japan.
Michiko MasudaDepartment of Respiratory Medicine, National Hospital Organization Kasumigaura Medical Center, Tsuchiura, Japan.
Hajime OsawaDepartment of Respiratory Medicine, National Hospital Organization Kasumigaura Medical Center, Tsuchiura, Japan.
Yuzuru KondoDepartment of Diagnostic Pathology, National Hospital Organization Kasumigaura Medical Center, Tsuchiura, Japan.
Yukio IshiiDepartment of Respiratory Medicine, National Hospital Organization Ibarakihigashi National Hospital, Tokai, Japan.
Nobuyuki HizawaDepartment of Respiratory Medicine, University of Tsukuba, Tsukuba, Japan.
National Hospital Organization · JPUniversity of Tsukuba · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 71-year-old non-smoker woman was admitted to our hospital because of left front chest pain. A computed tomography scan showed a large mass of >7.0 cm in the lower left part of the lung and multiple organ metastases in the liver, brain, bone, and left adrenal gland. Pathological analysis of a resected specimen obtained by bronchoscopy revealed keratinization. In addition, p40 was positive and thyroid transcription factor-1, synaptophysin, CD56, and chromogranin A were negative by immunohistochemistry. Programmed cell death ligand 1 expression was 1%-10%, and exon 19 deletion was detected. We diagnosed the patient with stage IVB lung squamous cell carcinoma and administered osimertinib. Osimertinib was later replaced with afatinib because of grade 3 skin rash. Overall, the size of the cancer was decreased. Furthermore, her symptoms, laboratory data, and computer tomographic findings markedly improved. In summary, we experienced a case of epidermal growth factor receptor-positive lung squamous cell carcinoma that was responsive to epidermal growth factor receptor tyrosine kinase inhibitors.

Indexed as

epidermal growth factor receptor mutationexon 19 deletion mutationLung squamous cell cancertargeted therapy

Identifiers

PMID36890803
PMCPMC9986888
OpenAlexW4323286936

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.